Advertisement

Topics

Fulvestrant in combination with palbociclib receives EU approval for HR-positive advanced breast cancer

05:34 EST 15 Nov 2017 | ecancermedicalscience

The European Commission (EC) has approved a new indication for fulvestrant in combination with a CDK4/6 inhibitor, palbociclib, for the treatment of hormone receptor-positive (HR ), human epidermal growth factor receptor 2 negative (HER2-) locally...

Original Article: Fulvestrant in combination with palbociclib receives EU approval for HR-positive advanced breast cancer

NEXT ARTICLE

More From BioPortfolio on "Fulvestrant in combination with palbociclib receives EU approval for HR-positive advanced breast cancer"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Endocrine Disorders
Endocrine disorders are grouped into two categories: hormone imbalance - when a gland produces too much or too little of an endocrine hormone development of lesions (such as nodules or tumors) in the endocrine system, which may or may not affect...